Molnupiravir Shortage Update: What Patients Need to Know in 2026

If your pharmacist has told you they don't carry molnupiravir — or you've driven to multiple pharmacies only to come up empty-handed — you're not imagining things. Even without an active FDA shortage declaration, molnupiravir (Lagevrio) can be genuinely difficult to find at the pharmacy level. Here's a clear-eyed update on what's happening with molnupiravir availability in 2026.

Is Molnupiravir Currently in Shortage?

As of 2026, molnupiravir is not listed on the FDA's official Drug Shortage Database. Merck (the manufacturer) continues to produce and commercially distribute Lagevrio through standard pharmacy channels. However, the absence of an official shortage doesn't mean the medication is easy to find. Localized supply gaps remain common — particularly at smaller pharmacies, in rural areas, and during COVID-19 seasonal surges.

A Brief History of Molnupiravir Supply Issues

Molnupiravir's availability history is closely tied to the COVID-19 pandemic response:

Late 2021: FDA granted Emergency Use Authorization in December 2021. The U.S. government purchased approximately 3.1 million courses for emergency distribution.

2022: Federal stockpiles were distributed through state health departments and Test to Treat locations. Availability was uneven — some areas had plenty while others struggled to access it.

May 2023: The COVID-19 Public Health Emergency ended. Distribution transitioned from federal management to standard commercial pharmacy channels. Retail prices rose sharply — to over $1,100 per course.

2024–2026: Commercially available through standard pharmacy channels. No FDA shortage declared. However, because molnupiravir is a third-line treatment with lower prescription volume, many pharmacies stock it inconsistently.

Why Patients Still Struggle to Find Molnupiravir

Even without a formal shortage, several factors make molnupiravir hard to find at the pharmacy level:

Low prescription volume: Pharmacies stock medications based on historical demand. Since Paxlovid is prescribed far more often, pharmacies may not reorder molnupiravir regularly.

No generic alternative: Lagevrio is a brand-only drug. There is no cheaper generic, limiting the number of suppliers and price competition.

High retail cost: At over $1,100 for a 5-day course, smaller pharmacies may not stock expensive slow-moving medications that tie up capital.

Seasonal demand spikes: COVID-19 surges in fall and winter can temporarily outpace pharmacy ordering, creating short-term local shortages.

What the Data Says About Molnupiravir Demand

Clinical guidelines from the NIH and IDSA rank molnupiravir third in preference — after Paxlovid and remdesivir. Most patients who are eligible for COVID antivirals and don't have contraindications will receive Paxlovid. This means molnupiravir demand is naturally lower, concentrated among patients with complex medication regimens or Paxlovid contraindications. This niche demand profile makes pharmacy stocking inconsistent.

What Patients Should Do Right Now

If you've been prescribed molnupiravir and can't find it, act quickly — you only have 5 days from symptom onset:

Call your prescriber immediately to let them know you cannot find the medication.

Use medfinder to check pharmacy availability near you without making dozens of calls yourself.

Expand your search radius — try pharmacies 10–20 miles away if your local options are exhausted.

Ask about alternative treatments if the window closes — your provider may be able to pivot to Paxlovid (with drug interaction management) or IV remdesivir.

How medfinder Helps During Supply Gaps

Even when molnupiravir isn't in shortage nationally, localized supply gaps hit individual patients hard. medfinder is a paid service that calls pharmacies near you to identify which ones have your medication in stock. You share your medication name, dosage, and location — medfinder does the calling and sends results to your phone. This is especially valuable during COVID surges when pharmacies that normally stock it run low.

For more context, see our post on why molnupiravir is hard to find in 2026.

Bottom Line

There is no active national shortage of molnupiravir in 2026, but pharmacy-level availability is inconsistent. Patients who need this medication should act fast, search broadly, and contact their provider if they're struggling — because every day within that 5-day treatment window matters.